| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MREO | American Depositary Shares representing Ordinary Shares | Sale | -$34.7K | -7.77K | -3.91% | $4.47 | 191K | Sep 12, 2024 | Direct | F1, F2, F3, F6 |
| transaction | MREO | American Depositary Shares representing Ordinary Shares | Sale | -$179K | -40K | -20.98% | $4.47 | 151K | Sep 12, 2024 | Direct | F1, F3, F5 |
| transaction | MREO | American Depositary Shares representing Ordinary Shares | Sale | -$68.8K | -16.3K | -10.81% | $4.22 | 134K | Sep 13, 2024 | Direct | F1, F2, F4 |
| transaction | MREO | American Depositary Shares representing Ordinary Shares | Sale | -$355K | -84K | -62.47% | $4.22 | 50.5K | Sep 13, 2024 | Direct | F1, F4, F5 |
| Id | Content |
|---|---|
| F1 | Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. |
| F2 | Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the 'Plan'), occurring on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
| F3 | The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc ("Mereo"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. |
| F4 | The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive. |
| F5 | The Reporting Person sold a total of 124,037 ADSs solely to pay tax obligations, including tax withholding obligations related to the exercise of stock options described in the Form 4 filed on September 13, 2024. |
| F6 | The total amount of securities beneficially owned on the reporting person's Form 4 filed on September 13, 2024 has been reduced by 44,296, which reflects ADSs withheld by the Issuer in connection with the net settlement of the stock option exercise on September 11, 2024 and inadvertently omitted from the September 13, 2024 filing. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3. |
Chief Patient Access and Commercial Planning